| Literature DB >> 31137882 |
Priyanka Reddy1,2, Kathryn Guthridge3, Simone Vassiliadis4, Joanne Hemsworth5, Inoka Hettiarachchige6, German Spangenberg7,8, Simone Rochfort9,10.
Abstract
Indole-diterpenes are an important class of chemical compounds which can be unique to different fungal species. The highly complex lolitrem compounds are confined to Epichloë species, whilst penitrem production is confined to Penicillium spp. and Aspergillus spp. These fungal species are often present in association with pasture grasses, and the indole-diterpenes produced may cause toxicity in grazing animals. In this review, we highlight the unique structural variations of indole-diterpenes that are characterised into subgroups, including paspaline, paxilline, shearinines, paspalitrems, terpendoles, penitrems, lolitrems, janthitrems, and sulpinines. A detailed description of the unique biological activities has been documented where even structurally related compounds have displayed unique biological activities. Indole-diterpene production has been reported in two classes of ascomycete fungi, namely Eurotiomycetes (e.g., Aspergillus and Penicillium) and Sordariomycetes (e.g., Claviceps and Epichloë). These compounds all have a common structural core comprised of a cyclic diterpene skeleton derived from geranylgeranyl diphosphate (GGPP) and an indole moiety derived from tryptophan. Structure diversity is generated from the enzymatic conversion of different sites on the basic indole-diterpene structure. This review highlights the wide-ranging biological versatility presented by the indole-diterpene group of compounds and their role in an agricultural and pharmaceutical setting.Entities:
Keywords: endophyte; fungi; lolitrems; mycotoxins; neurotoxin
Mesh:
Substances:
Year: 2019 PMID: 31137882 PMCID: PMC6563255 DOI: 10.3390/toxins11050302
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Indole-diterpene biosynthetic map sourced from KEGG pathways showing the enzymes responsible for producing indole-diterpene compounds at each step. Reproduced from [29,30,31].
A summary of the biological activities reported for intermediaries isolated from the indole-diterpene biosynthetic pathway and some synthetic derivatives.
| Compound Name | Toxicity as Per Biological Activity on Mice (mg of Compound/kg of Body Weight) | Observation on Mice | Biological Activity on BK/Maxi or | Biological Activity on Animal Model (EMG Activity/Observation in Sheep) |
|
|---|---|---|---|---|---|
| Lolitrem A | 2 mg/kg | Severe and prolonged tremor | ¯ | ¯ | [ |
| Lolitrem B | 0.5 to 8.0 mg/kg | Severe and prolonged tremor | IC50 = 4 nM (No recovery after wash out) | At 70 µg/kg dose, tremors were observed after 15 min and slowly increased in severity lasting for duration of 12 h. The reticulum and rumen showed inhibition after 20–30 min, coinciding with tremors. | [ |
| 31- | 4 mg/kg | Nontremorgenic | IC50 = 50 nM (>50% recovery after 10 min) | The lolitrem B isomer was administered at a dose of 70 µg/kg and there was no effect either on the skeletal muscle EMG activity or EMG activity of the reticulum and rumen. | [ |
| Lolitrem E | 2 mg/kg | Nontremorgenic | IC50 = 6 nM (No recovery after wash out) | ¯ | [ |
| Lolitrem E acetate | 16 mg/kg | Weakly tremorgenic | IC50 = 2 nM (No recovery after wash out) | ¯ | [ |
| 31- | 4 mg/kg | Slightly less tremorgenic than lolitrem B | ¯ | ¯ | [ |
| Lolitrem Fa | 4 mg/kg | Slightly less tremorgenic than lolitrem B | IC50 = 8 nM (No recovery after wash out) | ¯ | [ |
| Lolitrem M | Nontremorgenic | IC50 = 78 nM (>50% recovery after 10 min) | ¯ | [ | |
| Paxilline | 4 to 8 mg/kg and an 80 mg/kg dose | Severe but short term tremorgenicity compared to lolitrem B | Complete inhibition = 1 µM (recovery after wash out) | At 1.0 mg/kg dose, moderate to strong tremors; the onset was immediate after 2 min administration; tremors gradually disappeared over the next hour. EMG activity showed both excitatory and inhibitory on the reticulum and rumen. Also, within a minute of infusion, elevations of the EMG activity coincided with induction of marked tremoring. | [ |
| 13-Desoxypaxilline | 8 mg/kg | Nontremorgenic | < 50% inhibition = 30 µM | ¯ | [ |
| α-Paxitriol | 100 mg/kg | Lethargy and rough coats, also normal activities such as walking, rearing and preening were greatly reduced for several hours. Animals recovered to normal by 24 h post-injection. | ¯ | ¯ | [ |
| β-Paxitriol | 100 mg/kg | Lethargy and rough coats, also normal activities such as walking, rearing and preening were greatly reduced for several hours. Animals recovered to normal by 24 h post-injection. | ¯ | ¯ | [ |
| Lolitriol | 20 mg/kg | Nontremorgenic | IC50 = 196 nM (>50% recovery after 10 min) | ¯ | [ |
| Lolitriol acetate | - | Nontremorgenic | IC50 = 43 nM (>50% recovery after 10 min) | ¯ | [ |
| Lolitriol and β-Paxitrol | As a mixture: 16 mg/kg and 100 mg/kg respectively (200 µL dosage) | The single administration of both β-paxitriol and the nontremorgenic lolitriol proved lethal after an initial period of lethargy | - | - | [ |
| Lolilline | 8 mg/kg | Nontremorgenic | - | - | [ |
| 6,7-dehydroterpendole A | 8 mg/kg | Produced more intense tremors than terpendole C and K at the same dose level | - | - | [ |
| Terpendole C | 4 mg/kg and 8 mg/kg | A fast-acting tremorgen that produced more intense tremors than paxilline, 11-hydroxy12,13-epoxyterpendole K and 6,7-dehydro-11-hydroxy-12, 13 epoxyterpendole A at the same dose level, but the activity ceased after 2 h, as compared to paxilline which ceased after 6 h. | ¯ | ¯ | [ |
| Terpendole D, E, F, G, H and I | 8 mg/kg | Nontremorgenic | ¯ | ¯ | [ |
| Terpendole K | 8 mg/kg | Produced more intense tremors than paxilline, 11-hydroxy12,13-epoxyterpendole K and 6,7-dehydro-11-hydroxy-12,13 epoxyterpendole A at the same dose level | ¯ | ¯ | [ |
| Terpendole M | 8 mg/kg | Weakly tremorgenic | ¯ | ¯ | [ |
| 6,7-dehydro-11-hydroxy-12,13 epoxyterpendole A and 11-hydroxy12,13-epoxyterpendole K | 8 mg/kg | Mild tremors | ¯ | ¯ | [ |
| Mixture of 88.3% Penitrem A, 6.4% Penitrem B, 5.3% Penitrem E | ¯ | ¯ | A dose of 5.5 mg/kg showed no significant skeletal EMG activity, although exhibited strong inhibition on the reticulum and rumen. This was apparent at 15 to 30 min and lasted 2 h. The maximum period of inhibition coincided with the period of greatest tremoring. | [ | |
| Penitrem A | 0.75 mg/kg (dose range 0.5 mg/kg to 1.5 mg/kg) | Elicited moderate tremors. Tremor duration reported as several hours. | Fraction current blocked by 10 nM = 100% (no recovery after wash out) | Tremorgenic observation in sheep when given at a dose of 20 µg/kg intravenously. | [ |
| Penitrem E | 2.25 mg/kg (dose range 1.0 mg/kg to 3.6 mg/kg) | Elicited moderate tremors. Tremor duration reported as several hours. No difference to penitrem A in the rates of onset of tremors observed, and the symptomatology were like-wise similar. | - | - | [ |
| Paspaline | ¯ | ¯ | Slight inhibition at concentrations up to 1 µM | ¯ | [ |
| Paspalinine | 8 mg/kg | Short duration tremors | Fraction current blocked by 10 nM = 100% (no recovery after wash out) | ¯ | [ |
| Paspalicine | 250 mg/kg | Nontremorgenic | Fraction current blocked by 10 nM = 83% (recovery after wash out) | ¯ | [ |
| Paspalitrems | 14 mg/kg | Short duration tremors | Fraction current blocked by 10 nM of paspalitrem A and paspalitrem C = 98% and 100% respectively (no recovery after wash out) | ¯ | [ |
| Aflatrem | 1 mg/kg | Short duration tremors | Fraction current blocked by 10 nM = 100% (no recovery after wash out) | ¯ | [ |
| Janthitrem A | 4 mg/kg | Tremor duration was reported as 8 h and peaked at 15 min. Tremors produced were more intense than janthitrem B, from 2 h post exposure. | ¯ | ¯ | [ |
| Janthitrem B | 6 mg/kg | Tremor duration reported as 6 h and peaked at 30 min. Un-coordination and hypersensitivity to sound and touch is also reported. | ¯ | ¯ | [ |
a) Lolitrem F and 31-epi-lolitrem F have been reported to have a similar but slightly reduced tremorgenic activity compared to that reported for lolitrem B; however, Munday-Finch et al. assume that impurities present in lolitrem F and 31-epi-lolitrem F could have caused the slightly reduced activity [46].
Figure 2Structures of paxilline and selected derivatives.
Figure 3Structures of lolitrems A–N.
Figure 4Structures of lolitrem derivatives.
Figure 5Structures of penitrems A–F.
Figure 6Structures of paspaline and paspaline derivatives.
Figure 7Structures of terpendoles A–L and derivatives.
Figure 8Structures of sulpinines A–C and secopenitrem.
Figure 9Structures of emindoles.
Figure 10Structures of asporyzins.
Figure 11Structures of aflatrems.
Figure 12Structures of janthitrems.
Figure 13Structures of shearinines A–M.